The lack of transplantable tumors has limited assessment of graft versus tumor effects following hematopoietic cell transplantation in clinically relevant large animal models. We describe the derivation and characterization of porcine tumor cell lines with initial efforts of tumor transplantation using immunocompromised mice and highly inbred sublines of MGH MHCinbred miniature swine. Autopsies were performed routinely on swine that died unexpectedly or had suspicion of malignancy based on clinical symptoms or peripheral blood analysis. Tissue samples were obtained for pathology, phenotyped by flow cytometry, and placed in culture.
Introduction
Animal models of malignancy are valuable tools for studying cancer biology. Although rodent models have aided in elucidating mechanisms of oncogenesis and in developing treatment strategies, small animal systems are limited in their ability to accurately reflect all aspects of the disease conditions associated with human cancers. 1, 2 Translation from these small animal models towards the clinical setting is not always possible, as humans often have different responses and disease mechanisms. 3, 4 Since the life span of these animals is significantly shorter, it is also difficult to utilize them for longitudinal studies to investigate the efficacy and safety of new treatments. 5, 6 Large animals with greater genetic and physiologic similarities to humans can be used to bridge this translational gap. 7 Such models of malignant diseases rely on spontaneous neoplasms occurring in certain breeds, such as canine melanoma, or on induced tumors resulting from exposure to a carcinogen. [7] [8] [9] Virally induced tumor cells have also been used for evaluating imaging modalities and feasibility of interventional radiological techniques in dogs, but these systems may not necessarily resemble in situ malignancies of those organs. 10 The low incidence of disease and the length of time to disease onset limit practicality of these models for experimentation.
Non-myeloablative HCT protocols that achieve potent graft versus tumor (GVT) effects without graft versus host disease (GVHD) have been developed in rodent models.
11-13
Successful translation of these protocols to the clinic has been limited, however, with GVHD remaining a major complication. Our laboratory has developed minimally toxic HCT protocols in miniature swine that achieve stable engraftment across MHC barriers without GVHD. 14 The lack of available transplantable tumor lines in miniature swine has so far prohibited the direct evaluation
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Recently, histocompatible sublines of SLA dd animals have been established that accept reciprocal skin grafts. 15 Isolation of tumors and establishment of tumor cell lines from these animals should permit development of transplantable tumor models to assess GVT effects in miniature swine.
Over the past ten years, we have monitored our herd for the occurrence of malignancies, particularly hematologic cancers such as leukemias and lymphomas. From this surveillance, we now report our establishment of porcine tumor lines and our initial efforts of tumor transplantation.
Methods

Animals
MGH partially inbred MHC-defined miniature swine have previously been described in detail. 16, 17 
Detection and Diagnosis
Animals were under continuous surveillance for the development of abnormal symptoms and physical findings. The preliminary screen for malignancy included review of clinical symptoms, physical findings, complete blood count (CBC), and white blood cell (WBC) differential by manual count and flow cytometry. Based on this screen, animals suspected of malignancy were sacrificed and underwent an autopsy under aseptic conditions to obtain primary disease tissues.
Animals that died unexpectedly were also subject to autopsy under aseptic conditions for tissue harvest and for diagnostic purposes. The diagnosis of malignancies was based on the clinical findings, history, physical examination, CBC, histology, and phenotypic analysis by surface staining and flow cytometry of peripheral blood cells.
Tissue and Peripheral Blood Mononuclear Cell Harvest and Processing
At the time of autopsy, tissue samples from lymphoid, hematopoietic, and any organ that appeared abnormal at autopsy were obtained in a sterile manner. Samples were then processed by mechanical maceration and subsequent filtering with Hanks Buffered Salt Solution (HBSS) through a 40um cell strainer (Becton Dickinson 33 Data were analyzed using Winlist list mode analysis software (Verity Software House, Topsham, ME).
In vivo transfer of tumors into NOD/SCID mice
In an attempt to select for variants with in vivo growth potential, cultured tumor cell lines were transplanted into NOD/SCID mice (Jackson Laboratories, Bar Harbor, ME). Animals were 4-8 weeks of age and were housed in clean conditions. Animals were manually restrained and sterilely swabbed with a 70% alcohol solution at the site for intraperitoneal (IP) injection in the lower right abdominal quadrant. Sterile 23 to 27 gauge needles were used to deliver the sterile inoculum of tumor cells at a dose of ranging from 1-5 x 10 7 cells in a total volume of 0.2ml.
Tumor tissue was removed sterilely to obtain samples for cell culture, pathology, and surface phenotyping by flow cytometry. These tissue samples were also processed by mechanical maceration and subsequent filtering with Hanks Buffered Salt Solution through a 40um cell CyA whole blood levels between 400-800 ng/mL during the treatment period. Animals were monitored for tumor growth by palpation of injection sites. Blood samples from animals were analyzed for a complete blood count and for tumor growth after IV tumor administration by flow cytometry. If tumor growth was detected, animals were euthanized. Tissues were sterilely harvested and processed for analysis and for culture, as outlined above.
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Results
Incidence of Malignancies in MGH MHC-Defined Miniature Swine
From surveillance of our herd, we identified nineteen cases of malignancies. Ten of these cases were derived from animals with post-transplant lymphoproliferative disease (PTLD), a complication of either experimental hematopoietic cell or solid organ transplant protocols. The incidence of PTLD occurring in these protocols has been previously reported. [34] [35] [36] Since no experimental HCT recipients from the inbred sublines were used, all PTLD cases occurred outside of the highly inbred SLA dd sublines of animals. The remaining nine cases were spontaneously occurring malignancy. Of these cases, five occurred within highly inbred SLA dd histocompatible sublines. To determine the incidence of spontaneous, not transplant-related malignancy, we utilized our animal database consisting of data collected over the last ten years and evaluated the number of cases occurring in adult naïve animals greater than or equal to 24 months of age and unassigned to an experimental protocol. As most animals in our herd do not reach 24 months due to their use in experiments, only these animals were considered relevant for comparison. The overall incidence of spontaneous malignancy among susceptible animals (≥24 months of age) within these sublines was 2.5% (4/159), while disease incidence among all other haplotype lines was 1.3% (4/301), giving a p=0.64 (χ 2 =0.216). A similar comparison of disease in incidence in older populations (≥36 months) revealed a statistically significant incidence of 10% (4/40) in the histocompatible sublines versus 1.3% (3/223), giving a p=0.016 (χ 2 =5.763).
However, it is uncertain whether this is an accurate reflection of disease incidence in our miniature swine as there are a limited number of animals, particularly for the SLA dd subline, that reach this age. 
Diagnosed Malignancies Observed in Miniature Swine
The age, haplotype, and diagnosed malignancy of animals that developed disease are compiled in Table 1 . After the fifth generation (G5) of brother-sister mating, three parallel sublines with common ancestry at G5 were set up for further inbreeding. For the purposes of this study, we will refer to these distinct sublines as DD1, DD2, and DD3. For disease occurring in highly inbred SLA dd animals, the subline to which each animal belonged is also noted in Table 1 . Of the nineteen observed cases of malignancy, six cases were diagnosed as leukemia, eleven were lymphomas, and one was a non-identified carcinoma with lung involvement. All cases of leukemia occurred in adult animals ranging from 30 to 76 months at time of disease diagnosis.
Three cases occurred in inbred SLA dd animals and characterization of disease has been concurrently reported (Cho et al., submitted for publication). Only one case of lymphoma was a spontaneous neoplasm, which occurred in an inbred SLA dd adult animal 38 months old. The remaining ten cases of lymphoma were due to post-transplant lymphoproliferative disease (PTLD). [34] [35] [36] These cases occurred in adolescent animals between 3 to 7 months of age. This malignancy was histologically diagnosed as a non-specific carcinoma obtained from the lung at necropsy.
Clinical Presentation and Laboratory Findings of Animals at Initial Presentation
Gross Anatomic and Histologic Findings of Primary Tumors
In animals with lymphoma or PTLD, mild hepatosplenomegaly and diffuse lymphadenopathy which included prominent enlargement of mesenteric lymph node chain was observed at autopsy There was also histological evidence of diffuse infiltration consisting of large, pleiomorphic malignant cells containing heterochromatic nuclei. These cells were present throughout all vascularized tissues such as the kidney and the lung, and they were also prominent in the bone marrow ( Figure 2b ).
For
Establishment of Tumor Cell Lines
Of the nineteen cases of malignancy, tissues from eight animals grew into tumor cell lines. Since two phenotypically distinct cell lines were derived from lymph node (LCL-17016L) and PBMC (LCL-17016P) from animal 17016, these eight cases allowed for the establishment of nine distinct tumor cell lines. Characteristics of each line, including cell surface markers and doubling time, are summarized in Table 2 , while in vitro growth patterns are shown in Figure 3 .
All established tumor cell lines express surface MHC class I (dull) and MHC class II in addition to the pertinent markers listed in the last column of Table 2 . Each of the five lymphoma lines was established after obtaining primary tumors from involved lymph nodes and/or processed PBMC and placing these cells in culture. Tumor lines were considered established once they were able to be passaged continuously in culture for a minimum period of two months prior to freezing down for storage. The leukemia lines were established from cultures of either processed bone marrow or processed PBMC. Leukemia cell lines had positive staining for both myeloid markers CD16 and CD172a, which similar to pattern of cell surface markers on the primary tumors originally identified in diseased animals. Cell lines derived from lymphoma or PTLD lacked CD3 and CD5 found on T-cells and myeloid markers such as CD16 and CD172a. One line, LCL-17018, gained expression of myeloid marker CD172a after in vitro culture. With this one exception, the pattern of cell surface markers was similar to the primary tissues from which the lines were derived.
In Vivo Tumor Growth After Transfer into Immunocompromised Mice
To select variants with better in vivo growth potential, three tumor cell lines were initially tested for in vivo growth after transfer into NOD/SCID mice. The three tumor cell lines tested included LCL-13271, ML-12933, and CML-14736. Results of these experiments are summarized in Table 3 . Of these lines, only LCL-13271 demonstrated growth in vivo after intraperitoneal injection into mice (Figure 4 ). This particular cell line was isolated from a SLA ad animal 13271, that developed recipient-derived PTLD after a hematopoietic cell transplant. 34 Similar to the phenotype of some human lymphoma cell lines, 37 LCL-13271 had a stable phenotype after 72 passages based on continued expression of CD2 and CD25 while lacking other T cell markers such as CD3 and CD5 and lacking myeloid markers such as CD16 and CD172.
LCL-13271 cells were initially injected intraperitoneally into four NOD/SCID mice at a dose of 1.5x10 7 cells. After two months, animals had palpable masses that were harvested and evaluated by culture and histology. Abnormal cells with pleiomorphism and heterochromatic nuclei were found and were similar to what was seen in the primary tumor ( Figure 4 ). Cell suspensions from these tissues were confirmed as LCL-13271 in origin based on expression of CD2 and on the lack of other T cell and myeloid markers. For secondary transfer, these cells were then injected into three additional NOD/SCID mice at a dose of 5x10 7 cells, and these animals also grew palpable tumors. Tissues were harvested, processed, cultured, and frozen.
In Vivo Tumor Growth After Serial Transfer in Miniature Swine
Our initial efforts of in vivo experiments in miniature swine focused on tumors and recipient animals from within the highly inbred histocompatible subline of SLA dd miniature swine.
Although LCL-13271 demonstrated growth in immunocompromised mice, we did not test this particular line in miniature swine initially since it was derived from a SLA ad animal. Two established cell lines from SLA dd inbred animals -CML-14736 and ML-12933 -were expanded in culture and transplanted into miniature swine (Table 3) . Of these two lines, only CML-14736 demonstrated in vivo growth after intravenous and subcutaneous injection into irradiated miniature swine ( Figure 5 ). This particular line was established from the bone marrow cells from animal #14736 that was diagnosed with chronic myeloid leukemia. CML-14736 has been maintained in culture for over twenty passages and maintains the phenotype of the original tumor with surface expression of myeloid markers CD16 and CD172a and with a lack of T-cell markers CD3 and CD5.
CML-14736 did not grow in animals that received only CyA or were pre-treated with 100cGy or less TBI. Pre-treatment with 500cGy TBI allowed for growth after both intravenous and subcutaneous tumor administration, while 300cGy TBI was sufficient for growth following subcutaneous growth (Table 4 ). All tumor growth occurred within two weeks post-injection.
Animals that grew tumors after receiving SC injections developed palpable masses at the injection site (Figure 5a ). In one case of tumor growth following IV administration, abnormal malignant cells could be detected in the lung (Figure 5b ). Tissue sampled from these masses revealed abnormal cells with pleiomorphism and heterochromatic nuclei, suggestive of a neoplastic process, and also appeared similar in morphology to cells found in the primary bone marrow tissue of animal #14736. These cells seemed to be actively dividing based on the presence of mitotic figures. There was a lack of a cellular infiltrate, suggesting that the recipient did not mount an immune response to these cells. Immunohistochemistry of these tissues revealed positive staining for myeloid markers CD16 and CD172a, with negative staining for T cell marker CD3 (Figure 5c ). These findings were consistent with the phenotype of cultured CML-14736 cells. Cell suspensions were made from these lesions and had a phenotype identical
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Discussion
We have now identified and diagnosed nineteen cases of malignancies in miniature swine, including five cases within animals used to develop histocompatible sublines. With the exception of one case all were hematologic malignancies, either leukemias or lymphomas. The cases of lymphoma and leukemia were similar to human disease (Cho et al, manuscript in preparation). 34, 35 The incidence of post-transplant malignancy is high and restricted to certain haplotypes due to experimental protocols, and these results have been previously reported. [34] [35] [36] Overall incidence of spontaneous malignancy in our herd is low, but appears to be slightly increased in the highly inbred SLA dd sublines. However, this difference is not statistically significant when considering all animals ≥ 24 months of age and may reflect our increased awareness and lower threshold for suspicion of malignancy. There may also be a predilection for disease within this group, therefore suggesting a possible genetic etiology.
These malignancies have allowed us to successfully establish nine tumor cell lines, including three lines derived from highly inbred SLA dd animals. Our experience with tumor cell lines from these cases of malignancy is similar compared to the published experience of human tumor lines.
Human cell lines are typically considered established after six months of continuous growth and demonstrate immunophenotypic markers similar to their primary tumors. [38] [39] [40] For these porcine tumors, a minimum period of two months appeared to be sufficient to allow for in vitro tumor cell growth and establishment of a line. Although this is shorter than the time to establish human histocompatibility loci, there may be other minor or unknown antigens present which can still be recognized as foreign by the host immune system. [45] [46] [47] [48] Conversely, a lack of antigens or surface markers may also contribute, as markers necessary for in vivo growth of our porcine tumor lines Growth constant (k) = ln 2 / T, where T=doubling time in days *Note: Full panel includes the following markers -Negative IgG2a, MHC I, MHC II-DR, MHC II-DQ, CD1, CD2, CD3, CD4, CD5, CD8, CD9, CD16, CD21, CD25, CD172a, anti-mu heavy chain, and anti-kappa light chain. All tumor lines were found to be positive for MH ** LCL-17016L and LCL-17016P were both established from the same animal, but from different primary tissues. After growth in vitro, the cells derived from these tissues had different growth rates and surface marker patterns. 
